Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice

Vaccine

Volumn 29, Issue 45, 2011, Pages 8094-8100

  Gupta, Pallavi ^a   Singh, Manglesh Kumar ^a   Singh, Yamini ^a   Gautam, Vandana ^a   Kumar, Subodh ^a   Kumar, Om ^a   Dhaked, Ram Kumar ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Cytokine; Cytotoxicity; Hemolytic uremic syndrome; Isotyping; Shiga toxin

Indexed keywords

ANTISERUM; CYTOKINE; FREUND ADJUVANT; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; SHIGA TOXIN; SHIGA TOXIN B; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOMODULATION; KIDNEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHIGELLA DYSENTERIAE; SHIGELLOSIS; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; CYTOKINES; DYSENTERY, BACILLARY; FEMALE; FREUND'S ADJUVANT; HISTOCYTOCHEMISTRY; IMMUNOGLOBULIN G; KIDNEY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; PROTEIN SUBUNITS; SHIGA TOXIN; SHIGELLA DYSENTERIAE; SHIGELLA VACCINES; SPLEEN; VACCINES, SYNTHETIC;

EID: 80053626469     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.040     Document Type: Article

References (43)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implication for vaccine development and implementation of control strategies. Bull WHO 1999, 77:651-666.
2. http://www.cdc.gov/ecoli/2011/ecolio104.
3. ObrigTG, Louise C.B., Lingwood C.A., Boyd B., Barley-Maloney L., Daniel T.O. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993, 268:15484-15488.
4. Noel J.M., Boedeker E.C. Enterohemorrhagic Escherichia coli: a family of emerging pathogens. Dig Dis 1997, 15:67-91.
5. Karmali M., Petric M., Lim C., Fleming P.C., Arbus G.S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985, 151:775-782.
6. Donohue-Rolfe A., Keusch G.T., Edson C., Thorley-Lawson D., Jacewicz M. Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. J Exp Med 1984, 160:1767-1781.
7. Austin P.R., Jablonski P.E., Bohach G.A., Dunker A.K., Hovde C.J. Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity. Infect Immun 1994, 62:1768-1775.
8. Lindberg A.A., Brown J.E., Stromberg N., Westling-Ryd M., Schultz J.E., Karlsson K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem 1987, 262:1779-1785.
9. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. The site of action of a Verotoxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-glycosidase activity of the toxins. Eur J Biochem 1988, 171:45-50.
10. Suh J.K., Hovde C.J., Robertus J.D. Shiga toxin attacks bacterial ribosomes as effectively as eucaryotic ribosomes. Biochemistry 1998, 37:9394-9398.
11. Boyd B., Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron 1989, 51:207-210.
12. Ohmura M., Yamamoto M., Tomiyama-Miyaji C., Yuki Y., Takeda Y., Kiyono H. Nontoxic Shiga toxin derivatives from Escherichia coli possesses adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation. Infect Immun 2005, 73:4088-4097.
13. Donohue-Rolfe A., Acheson D.W.K., Kane A.V., Keusch G.T. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun 1989, 57:3888-3893.
14. Downes F.P., Barrett T.J., Green J.H., Aloisio C.H., Spika J.S., Strockbine N.A., et al. Affinity purification and characterization of Shiga-like toxin II and production of toxin specific monoclonal antibodies. Infect Immun 1988, 56:1926-1933.
15. Harari I., Donohue-Rolfe A., Keusch G.T., Arnon R. Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity. Infect Immun 1988, 56:1618-1624.
16. Islam M.S., Stimson W.H. Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. J Clin Lab Immunol 1990, 33:11-16.
17. Smith M.J., Carvalho H.M., Melton-Celsa A.R., O'Brien A.D. The 13C4 Monoclonal antibody that neutralizes Shiga toxin type1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun 2006, 74:6992-6999.
18. Steven T.S., Panda A., Khan A.Q., Kriel E.H., Maciel M., Livio S., et al. A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis). Comp Med 2010, 60:54-61.
19. Rubhana R., Lindberg A.A., Wretlind B., Bardhan P.K., Andersson U.L.F., Andersson J.A.N. Persistence of local cytokine production in Shigellosis in acute and convalescent stages. Infect Immun 1995, 63:289-296.
20. Haicheur N., Benchetrit F., Amessou M., Leclerc C., Falguieres T., Fayolle C., et al. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol 2003, 15:1161-1171.
21. Smith M.J., Teel L.D., Carvalho H.M., Melton-Celsa A.R., O'Brien A.D. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006, 24:4122-4129.
22. Gupta P., Singh M.K., Singh P., Tiwari M., Dhaked R.K. Antibodies against recombinant Shiga toxin subunit B neutralize Shiga toxin toxicity in HeLa cells. Protein Pept Lett 2010, 17:774-781.
23. Zhu C., Yu j., Yang Z., Davis K., Rios H., Wang B., et al. Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin B subunit. Clin Vac Immunol 2008, 15:359-366.
24. Ludwig K., Karmali M.A., Sarkim V., Bobrowski C., Petric M., Karch H., et al. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2001, 39:2272-2279.
25. Boyd B., Richardson S., Gariepy J. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin. Infect Immun 1991, 59:750-757.
26. Imai Y., Nagai R., Ono Y., Ishikawa T., Nakagami H., Tanikawa T., et al. Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization. Infect Immun 2004, 72:889-895.
27. Betting D.J., Kafi K., Abdollahi-Fard A., Hurvitz S.A., Timmerman J.M. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol 2008, 181:4131-4140.
28. Garcia-Selles J., Pascual A., Funes E., Pagan J.A., Lopez J.D., Negro J.M., et al. Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica. Allergol Immunopathol 2003, 31:63-69.
29. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
30. Machy P., Serre K., Baillet M., Leserman L. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains. J Immunol 2002, 168(3):1172-1180.
31. Wolski V.M., Soltyk A.M., Brunton J.L. Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants. Infect Immun 2001, 69:579-583.
32. Karpman D., Andreasson A., Thysell H., Kaplan B.S., Svanborg C. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995, 9:694-699.
33. Eisenhauer P.B., Jacewicz M.S., Conn K.J., Koul O., Wells J.M., Fine R.E., et al. Escherichia coli Shiga toxin 1 and TNF-α induce cytokine release by human cerebral microvascular endothelial cells. Microb Pathog 2004, 36:189-196.
34. Van Damme J., Cayphas S., Snick J.V., Conings R., Put W., Lenaerts J.P., et al. Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). Eur J Biochem 1987, 168:543-550.
35. Bertolini J.N., Benson E.M. The role of human interleukin-6 in B-cell isotype regulation and differentiation. Cell Immunol 1990, 125:197-209.
36. Bass H.Z., Yamashita N., Clement L.T. Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. II. Differential effects of IL-6 on the helper cell-independent generation of CTL from CD8+ precursor subpopulations. J Immunol 1993, 151:2895-2903.
37. Luger T.A., Krutmann J., Kirnbauer R., Urbanski A., Schwarz T., Klappacher G., et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol 1989, 143:1206-1209.
38. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckman M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-330.
39. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798.
40. Moingeon P., Haensler J., Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001, 19:4363-4372.
41. Snapper C.M., Mond J.J. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993, 14:15-17.
42. Boris L., Rosenwasser L.J. Update on cytokines. J Allergy Clin Immunol 1996, 3:719-733.
43. Oloomi M., Bouzari S., Ajdary S. Immune responses of mice immunized with active recombinant Shiga toxin and its derivatives. Iran J Allergy Asthma Immunol 2008, 7:53-60.